Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B

Cited by (211)

Items 101–200 of 211

1. Decanoylcarnitine Improves Liver Mitochondrial Dysfunction in Hepatitis B Virus Infection by Enhancing Fatty Acid β-Oxidation
   Ye Sun, Q L Chen, Yu-Xiao Liu, Mengfan Jiao, Zixing Dai, Xiaoxue Hou, Rui Liu, Yuwen Li, Chuanlong Zhu · 2025 · The Journal of Infectious Diseases
2. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan
   Wei Jiang, Changhai Liu, Dongbo Wu, Youjuan Wang, Hong Tang · 2021 · Bioscience Reports
3. Network Pharmacology and Molecular Docking Study on the Multi-Target Mechanisms of Aloe vera for Non-Alcoholic Steatohepatitis Treatment
   Tấn Khanh Nguyễn, Huy Hieu Phung, Won Jun Choi, Hee‐Chul Ahn · 2022 · Plants
4. Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
   Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Chao Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C Cheung et al. · 2024 · Journal of Viral Hepatitis
5. Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B
   Cecy Maria de Lima Santos, Matheus Duarte Brito, Pedro Alves Soares Vaz de Castro, Thais Pontello de Vries, Nataly Lopes Viana, Marta Paula Pereira Coelho, Olívio Brito Malheiro, Tatiana Bering, Marı́a Cristina González, Rosângela Teixeira et al. · 2022 · World Journal of Hepatology
6. The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase
   Yuting Diao, Danqing Hu, Xue Hu, Peng Wang, Xiaojing Wang, Xiaoping Luo, Hongwu Wang, Qin Ning · 2022 · Infectious Diseases and Therapy
7. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection
   Merve Sefa Sayar, Dilek Bulut, Ali Acar · 2022 · Arab Journal of Gastroenterology
8. Advanced Liver Fibrosis Is Associated with Necroinflammatory Grade but Not Hepatic Steatosis in Chronic Hepatitis B Patients
   Yi‐Cheng Chen, Chao‐Wei Hsu, Wen‐Juei Jeng, Chun‐Yen Lin · 2021 · Digestive Diseases and Sciences
9. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model
   Yuanqin Duan, Zhiwei Chen, Hu Li, Wei Shen, Yi Zeng, Mingli Peng, Peng Hu · 2021 · Frontiers in Molecular Biosciences
10. Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure
    Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai · 2022 · Gut and Liver
11. Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
    Shih-Chieh Chien, Yih‐Jyh Lin, Chun‐Te Lee, Yen‐Cheng Chiu, Tsung-Ching Chou, Hung‐Chih Chiu, Hung‐Wen Tsai, Che-Min Su, Tsung-Han Yang, Hsueh‐Chien Chiang et al. · 2022 · Viruses
12. Association between micronutrients intake and metabolic-associated fatty liver disease: a cross-sectional study based on the National Health and Nutrition Examination Survey
    Junzhen Hou, Qi-wei Wu, Li Rita Zhang · 2023 · Journal of Nutritional Science
13. Fatty Liver Disease
    DINA G. TINIAKOS, Quentin Mark Anstee, Elizabeth M. Brunt, Alastair D. Burt · 2023 · Elsevier eBooks
14. Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis
    Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei‐Chien Tsai, Youwen Tan, Hidenori Toyoda, Qinglei Zeng, Huy Ngoc Trinh, Yao‐Chun Hsu et al. · 2025 · Hepatology
15. ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study
    Christine Y. Chang, Leslie Yeeman Kam, Nolan H. Dang, Ramsey C Cheung, Mindie H. Nguyen · 2021 · Digestive Diseases
16. The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies
    Elliot B. Tapper, Charlotte Fleming, Adriana Rendon, João Diogo da Rocha Fernandes, Pierre Johansen, Margarida Augusto, Sunita Nair · 2022 · Gastro Hep Advances
17. Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
    Lung‐Yi Mak · 2024 · Journal of Liver Cancer
18. Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem Pieter Brouwer, Keyur Patel, Marı́a Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgür M. Koc et al. · 2025 · Alimentary Pharmacology & Therapeutics
19. Non-alcoholic fatty liver disease: time for changes
    T.I. Yefimenko, Myroslava Mykytyuk · 2021 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
20. Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B
    Manus Rugivarodom, Ananya Pongpaibul, Siwaporn P. Chainuvati, Supot Nimanong, Watcharasak Chotiyaputta, Tawesak Tanwandee, Phunchai Charatcharoenwitthaya · 2022 · Journal of Clinical and Translational Hepatology
21. Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis
    Sixing Shen, Lingyan Pan · 2024 · Experimental and Therapeutic Medicine
22. Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study
    Xiaohui Fang, Yuhang Yin, Haonan Zhao, Cai’e Wang, Hui Li, Yiyang Shang, Jiayu Li, Yue Gao, Nahúm Méndez‐Sánchez, Xingshun Qi · 2024 · Frontiers in Medicine
23. Dawn of an era of effective treatments for MAFLD
    Cameron Gofton, Jacob George · 2024 · Portal hypertension & cirrhosis
24. Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study
    Yendewa, George A., Elangovan, Abbinaya, Olasehinde, Temitope, Mulindwa, Frank, Cater, Mackenzie G., Salata, Robert A., Jacobson, Jeffrey M. · 2025 · Frontiers in Immunology
25. Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
    Jun Wang, Hongzhou Lu, Qian Li · 2024 · Frontiers in Immunology
26. The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis
    Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang · 2024 · Heliyon
27. New Aspects of Non-alcoholic Fatty Liver Disease
    Vladislav Vladimirovich Tsukanov, Krasnoyarsk, Russian Federation, Alexander Viktorovich Vasyutin, Yu.L. Tonkikh · 2021 · Doctor Ru
28. Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD
    Wenhui Wu, Qiang Gao, Suping Hai, Xitang Li, Binghui Yu, Junjian Hu, Feiyang Xu, Xizhe Zheng, Yuanyuan Wang, Awang Danzeng et al. · 2026 · Gut
29. Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease
    Jian Wang, Jiacheng Liu, Yilin Liu, Ruifei Xue, Jie Zhan, Suling Jiang, Li Wang, Xiaomin Yan, Yali Xiong, Juan Xia et al. · 2022 · Hepatology Research
30. Problems and Challenges Associated with Renaming Non-alcoholic Fatty Liver Disease to Metabolic Associated Fatty Liver Disease
    Minghui Zeng, Lin Chen, Yuqin Li, Yuqiang Mi, Liang Xu · 2023 · Infectious Diseases & Immunity
31. Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score
    Thai N. Truong, Trang Ngoc Doan Pham, Long Bao Hoang, Van Thi Thuy Nguyen, Hang Viet Dao, Diem Vu Bich Dao, Saleh Ali Alessy, Thuy Thi Thu Pham, Thuy Thi Thu Pham, Linh Duc Duy Nguyen et al. · 2023 · BMC Cancer
32. Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma
    Ibrahim Ayada, Jiajing Li, Willem Pieter Brouwer, Robert Jacobus de Knegt, Qiuwei Pan · 2024 · Hepatology International
33. Effect of aerobic exercise training on the fat fraction of the liver in persons with chronic hepatitis B and hepatic steatosis: Trial protocol for a randomized controlled intervention trial— The FitLiver study
    Sofie Jespersen, Peter Plomgaard, Sten Madsbad, Adam Espe Hansen, Thomas Bandholm, Bente Klarlund Pedersen, Christian Ritz, Nina M Weis, Rikke Krogh‐Madsen · 2023 · Trials
34. High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis
    İlkay Ergenç, Pinar Gokcen, Gupse Adali, Haluk Tarik Kani, Coskun Ozer Demirtas, Feyza Gunduz, Cigdem Ataizi Celikel, Yusuf Yilmaz · 2021 · Hepatology forum/Hepatology forum (Online)
35. Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B
    Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth · 2025 · Gastroenterology report
36. The Effect of MAFLD on Hepatocarcinogenesis in HBeAg-negative Patients with Undetectable HBV-DNA under NA Therapy: A Multicenter Study
    Keisuke Amano, Tomoya Sano, Tatsuya Ide, Dan Nakano, Tsubasa Tsutsumi, Teruko Arinaga‐Hino, Machiko Kawaguchi, Shingo Hirai, Ichiro Miyajima, Takuji Torimura et al. · 2025 · Internal Medicine
37. Patients with chronic hepatitis B exhibiting significant inflammation and fibrosis should pay particular attention to the status of hepatic steatosis during antiviral therapy
    Bingqing Yang, Tianyuan Yang, Chenxue Hou, Yue Li, Qi Wang · 2025 · Virology Journal
38. Chronic Hepatitis B Infection: Patient Guidance
    Lung‐Yi Mak, Jimmy Che‐To Lai, Ken Liu, Rashid Nok-Shun Lui, Sakkarin Chirapongsathorn, Kuo Chao Yew, Mara Teresa Panlilio, Cosmas Rinaldi Adithya Lesmana, Ruveena Bhavani Rajaram, Liang Shen et al. · 2025 · Journal of Gastroenterology and Hepatology
39. Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management
    Willem Pieter Brouwer, Luisa Vonghia, Maja Sofie Thiele, Jörn Markus Schattenberg, Foteini Anastasiou, Sonja Beckmann, Elisabetta Bugianesi, Laurent Castéra, Cyrielle Caussy, Ahmed Cordie et al. · 2026 · JHEP Reports
40. Special Issue: “Updates on HBV Infection”
    Isabelle Chemin, Flor Helene Pujol · 2022 · Microorganisms
41. Disease severity and antiviral response in patients with chronic hepatitis B with non-obese NAFLD
    Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang · 2023 · Journal of the Formosan Medical Association
42. Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus
    Huadong Li, Yanan Liu, Shuang Wu, Xufeng Quan, Xiaoyan Wang, Tiandan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang et al. · 2024 · World Journal of Hepatology
43. Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
    Changtian Su, Qin Yang · 2022 · Frontiers in Pharmacology
44. Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease
    Mariam Ragheb, Micah Grubert Van Iderstine, Gerald Yosel Minuk, Nabiha Faisal · 2024 · Canadian Liver Journal
45. Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
    Бацких Сергей Николаевич, E. V. Vinnitskaya, Сбикина Евгения Сергеевна, Ж. В. Борунова, Alexey Dorofeev, Yu.G. Sandler · 2020 · Russian Journal of Gastroenterology Hepatology Coloproctology
46. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study
    Oscar Hou In Chou, Jing Ning, Raymond Ngai Chiu Chan, Cheuk To Chung, Helen Ye Rim Huang, Kenrick Ng, Edward Christopher Dee, Sharen Lee, Apichat Kaewdech, Tong Liu et al. · 2022 · medRxiv
47. Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure
    Ruimin Lai, Li-Xi Yao, Shan Lin, Jiahui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu · 2024 · Expert Review of Gastroenterology & Hepatology
48. Development of a simple metabolic score to predict liver fibrosis risk in chronic hepatitis B patients: A retrospective cross-sectional study
    Li Liu, Ye Peng, Qiuping Gu, Zeng Ling, Lijuan Liang, Yingfeng Wei · 2025 · Journal of International Medical Research
49. Impact of cardiometabolic risk factors on hepatocellular carcinoma incidence in patients with chronic hepatitis B: A retrospective cohort study
    Chanavee Toh, Kedsiree Sanit, Pimsiri Sripongpun, Naichaya Chamroonkul, Suthat Liangpunsakul, Teerha Piratvisuth, Apichat Kaewdech · 2026 · PLoS ONE
50. Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection
    Talal K Bhatti, Joseph K. Lim · 2026 · World Journal of Gastroenterology
51. Diagnostic Efficacy of Vibration‐Controlled Transient Elastography in Patients With Metabolic Dysfunction–Associated Liver Disease and Chronic Hepatitis B
    Yaoyu Liu, Zhizhen Huang, Xinya Lan, Min Jia, Xiaoting Zheng, Min Hu, Huiying Luo, Luyun Zhang, Xuejing Li, Shaodong Chen et al. · 2024 · Gastroenterology Research and Practice
52. Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease
    Pengyan Zhang, Zhenqiu Liu, Hong Xia Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang · 2022 · European Journal of Gastroenterology & Hepatology
53. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs
    Yuichi Hiyama, Hatsue Fujino, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki et al. · 2024 · Hepatology Research
54. Does hepatic steatosis impact chronic hepatitis B?
    Terry Cheuk‐Fung Yip, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong · 2022 · Hepatology
55. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
    Pin‐Nan Cheng, Ming‐Lung Yu · 2024 · Clinical and Molecular Hepatology
56. Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha
    Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo et al. · 2025 · Journal of Viral Hepatitis
57. Évolution de la nomenclature des maladies hépatiques stéatosiques : vers un changement de paradigme
    Philippe Halfon · 2025 · La Revue de Médecine Interne
58. The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
    Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, 高潔如, Yuqiang Mi, 蒯文涛, 向慧玲, Liang Xu · 2026 · Frontiers in Immunology
59. State-of-the-art and emerging antivirals for chronic hepatitis B infection
    Μargarita Papatheodoridi, George Papatheodoridis · 2022 · Expert Opinion on Pharmacotherapy
60. Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
    You-Wen Tan, Jiamin Wang, Xingbei Zhou · 2023 · World Journal of Hepatology
61. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
    Guanglin Xiao, Hong Ren · 2024 · Journal of Hepatology
62. Three-dimensional organ segmentation-derived CT attenuation parameters for assessing hepatic steatosis in chronic hepatitis B patients
    Jeongin Yoo, Ijin Joo, Sun Kyung Jeon, Junghoan Park, Eun Ju Cho · 2025 · Scientific Reports
63. Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study
    Pınar Ergen, Burcu Işık, Ferhat Arslan, Fatma Yılmaz Karadağ, Özlem Aydın, Yasemin Çağ, Saadet Yazıcı, Ayşe Canan Üçışık · 2021 · Medeniyet Medical Journal
64. The function role of HIGD1A in nonalcoholic steatohepatitis from chronic hepatitis B
    Minran Li, Jinzhong Li, Dehua Wang, Tao‐yuan Li, Li-hong Ye, Xujing Liang, Hai-cong Zhang, Zhiquan Liu, Xuedong Zhang, Junqing Li et al. · 2023 · Scandinavian Journal of Gastroenterology
65. Perilipin 2 inhibits replication of hepatitis B virus deoxyribonucleic acid by regulating autophagy under high-fat conditions
    M. Victoria Delpino, Jorge Fabián Quarleri · 2024 · World Journal of Virology
66. An Overview of Non-alcoholic Fatty Liver Diseases (NAFLD)
    Ju‐Seop Kang, Hyun-Jin Kim, So-Jung Lim, Sang‐Won Lee, Inyoung Hwang · 2025 · IntechOpen eBooks
67. Impact of steatotic liver disease on hepatitis B-related hepatocellular carcinoma: MRI manifestation and prognostic potential
    Beixuan Zheng, Yuyao Xiao, Fei Wu, Chun Yang, Ruofan Sheng, Mengsu Zeng · 2025 · British Journal of Radiology
68. Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
    Ankur Jindal, Manoj Kumar · 2025 · Hepatology International
69. Diagnostic value of LPRI for assessing advanced liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease
    Min Wang, Huaxiao Chen, JiaEn Yang, Xueting Huang, Runyan He, Baohui Pei, Xiaolu Wu, Yanneng Kang, Longhao Xu · 2026 · BMC Gastroenterology
70. Clinical and histopathological features of chronic hepatitis B with normal alanine aminotransferase levels with or without concomitant non-alcoholic fatty liver disease
    Wencong Li, Shiheng Liu, Weiguang Ren, Xiaoxiao Zhang, Lingdi Liu, Fang Han, Ying Zhang, Yuemin Nan, Suxian Zhao · 2026 · Frontiers in Medicine
71. Metabolically associated fatty liver disease: What hepatologists need to know about this systemic disease
    Alexander L. PLAKIDA, Ольга Юшковська, Lidia Elżbieta Sierpińska · 2026 · World Journal of Hepatology
72. Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
    Hung‐Wei Wang, Hsueh‐Chou Lai, Wei‐Fan Hsu, Sheng‐Hung Chen, Yi‐Chun Kuo, Cheng‐Yuan Peng · 2026 · Annals of Medicine
73. Diagnostic performance of ultrasound-derived fat fraction for grading hepatic steatosis in patients with chronic liver diseases: a multicenter study
    JiaHao Han, Lixin Yang, 褚勵丞, Kexin Lou, Qun Zhang, Pingping Wang, Huiming Shen, JIA LIN LI, Zuowei Bao · 2026 · European Radiology
74. Effectivity and safety of TAF in CHB patients with concurrent MASLD: a real-world study
    Haifeng Zhang, Yong Zhou, Jun Qing Yu, Qingxi Wang, Xiaoyu Wang, Jing Chen, Jiaqi Yu, Bing Qiao, Zhensheng Liu · 2026 · BMC Gastroenterology
75. Head‐to‐Head Comparison of Four Ultrasound Elastography Techniques in Detecting Advanced Fibrosis
    JiaHao Han, 褚勵丞, Lixin Yang, Kexin Lou, Guangbin Dou, Huiming Shen, Xiaojun Cheng, Zuowei Bao, Jia Li · 2026 · Portal hypertension & cirrhosis
76. Concomitant Liver Steatosis in Chronic Hepatitis B Virus Infection Is Linked to a Distinct Cytokine Profile and Reduced Viral Load
    Katharina John, Marie-Louise Voss, Sherin Al Aoua, Martin Franck, Christine Susanne Falk, Heiner H. Wedemeyer, Klaus Schulze‐Osthoff, Heike Bantel · 2026 · The Journal of Infectious Diseases
77. Metabolic dysfunction-associated fatty liver disease in chronic hepatitis B: dual effects on hepatocarcinogenesis and evolving strategies for risk prediction
    Huihui Tao, Yuxin Duan, Guoyang Yu, Wei Yan, Jianhua Yin · 2026 · Frontiers in Immunology
78. The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B
    Alaa Mohamed Mostafa, Yasser Mahrous Fouad, Nadia Abdelaaty Abdelkader, Omar Magdy, Nehal Refaat Raouf, Mohammed Eslam · 2026 · Scientific Reports
79. Impact of nonalcoholic fatty liver disease on the response to pegylated interferon-α therapy in patients with chronic hepatitis B
    Huiqing Liang, Y D Xie, Yan Dai, Xiaorong Yang, Xiaoting Zheng, JiaEn Yang, Liu Y, Chuncheng Wu, S Y Chen, Manying Zhang et al. · 2026 · Microbiology Spectrum
80. Hepatitis Viruses: Hepatocellular Carcinoma
    Danbi Lee, Ju Dong Yang, Roongruedee Chaiteerakij, Lewis Rowland Roberts · 2023 · Springer eBooks
81. Evaluation of Hepatic Fibrosis and Hepatic Steatosis by Pulse Elastography (FIBROSCAN/CAP) in Asymptomatic Patients about 170 Cases at the Donka CHU National Hospital in Conakry
    Mamadou Sarifou Diallo, Oumarou Youssouf, Abdoulatif Yaogo, Djenabou Diallo, Diallo Kadiatou, Thierno Amadou Wann, Diallo Ahmed Tidiane, Mamadou Lamine Yaya Bah, Mamdou Diakhaby, Kanté Mamadou Aliou et al. · 2024 · Open Journal of Gastroenterology
82. Chronic Hepatitis B and Fatty Liver–Weal or Woe?
    Jie Li, Linda L Henry, Mindie H. Nguyen · 2022 · The American Journal of Gastroenterology
83. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
    Sinead Carlson, Karl Vaz, Adam R. Peterson · 2023 · Journal of Hepatology
84. Liver
    Furqan Shafqat, Shafeeq Ur Rehman, Muhammad Sajjad Khan, Kamal Niaz · 2023 · Elsevier eBooks
85. Letter to the Editor: Impact of Nonalcoholic Steatohepatitis on Liver‐Related Outcomes in Chronic Hepatitis B
    Rui Huang, Jian Wang, Zhaoping Zhang, Xiaomin Yan, Chao Wu · 2019 · Hepatology
86. Letter to the Editor: Chronic Hepatitis B and Nonalcoholic Steatohepatitis: Is “Fat” All Bad?
    Jie Li, Ramsey C Cheung, Mindie H. Nguyen · 2019 · Hepatology
87. Recent Advances in the Diagnosis and Treatment of Chronic Liver Diseases
    Hirayuki Enomoto · 2022 · MDPI eBooks
88. NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study
    Jian Wang, Sufang Lu, Ruifei Xue, Yuanwang Qiu, Yuxin Chen, Jia‐Cheng Liu, Renling Yao, Li Zhu, Jie Zhan, Suling Jiang et al. · 2022 · Research Square
89. Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C
    Qianwen Zhao, Yunlei Deng · 2022 · Alimentary Pharmacology & Therapeutics
90. Persistent steatosis retards fibrosis regression during anti-HBV treatment in patients with chronic HBV infection
    Mengyang Zhang, Shuyan Chen, Xiaoning Wu, Jialing Zhou, Tailing Wang, Hui Liu, Xinyan Zhao, Bingqiong Wang, Xinyu Zhao, Yuanyuan Kong et al. · 2023 · Research Square
91. Tiếp cận chẩn đoán bệnh gan nhiễm mỡ liên quan chuyển hóa (Metabolic associatedfatty liver disease - MAFLD)
    Phương Trần Ngọc Lưu, Thư Trần Phạm Phương · 2023 · Pham Ngoc Thach Journal of Medicine and Pharmacy
92. PREDICTORS OF HEPATOCYTES CYTOLYSIS OF INSULIN RESISTANT RATS UNDER CONDITIONS OF PRE- AND POSTNATAL IODINE DEFICIENCY
    В. Б. Стецев'ят, Nataliya Voronych-Semchenko, Mykola Bahrii, T.V. Huranych · 2023 · Fìzìologìčnij žurnal
93. Nonalcoholic Fatty Liver Disease Versus Metabolic Associated Fatty Liver Disease
    Sebastian Zenovia, Irina Gîrleanu · 2023 · Springer eBooks
94. Identification the shared pathogenesis between chronic hepatitis B and non-alcoholic fatty liver disease: Evidence from transcriptome data
    Yan Xiang Yang, Feilin Ge, Shuanglin Qin, Chen Luo, Xiaohe Xiao, Zhaofang Bai, Chenglin Tang · 2023 · Gastroenterology & Endoscopy
95. High Incidence Rate of Computed Tomography–Measured Steatotic Liver Disease in Men With and Without HIV Infection
    Jennifer C. Price, Gayle Springer, Eric C. Seaberg, Matthew Jay Budoff, Susan L. Koletar, Claudia Hawkins, Mallory D. Witt, Wendy S. Post, Chloe L. Thio · 2023 · The American Journal of Gastroenterology
96. Targeted Screening for Viral Hepatitis Among Various Ethnic Groups in Amsterdam, the Netherlands
    Anne‐Marieke van Dijk, Cas J. Isfordink, Anders C. Boyd, Henrike Galenkamp, Janke Schinkel, Maria Prins, Robert Bart Takkenberg, Onno Holleboom, Marc van der Valk · 2024 · Hepatitis Monthly
97. Fatty liver and viral hepatitis: Prevalence, risk factors, natural course, pathogenesis, and management
    Ming‐Lun Yeh, Jee‐Fu Huang, Ming‐Lung Yu · 2024 · Elsevier eBooks
98. Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B
    Xinrong Zhang, Vy H. Nguyen, Leslie Yeeman Kam, Scott Douglas Barnett, Linda L Henry, Ramsey C Cheung, Mindie H. Nguyen · 2024 · The Journal of Infectious Diseases
99. Non-invasive Assessment of Advanced Fibrosis and Steatosis in Chronic Hepatitis B Patients with Comorbid NAFLD
    Zhenhua Zhou, Feng Chen, Rongrong Zou, Qianhui Li, Xiaomin Xu · 2025 · Hepatitis Monthly
100. Unhealthy Behaviours and All‐Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta ( ANRS CO22 HEPATHER )
     Clémence Ramier, Fabrice Carrat, Vincent Di Beo, Lucia Parlati, Marta Lotto, Fabienne Marcellin, Camélia Protopopescu, Patrizia Carrieri, Marc Bourlière, the ANRS/AFEF HEPATHER study group · 2025 · Journal of Viral Hepatitis